Active Biotech AB (FRA:BTP) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BTP Active Biotech AB FRA:BTP
34 GF Score
Price €0.47
GF Value €0.13
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Net Loan?

Net Loan only applies to banks and insurance companies.

FRA:BTP
34GF Score
Active Biotech AB FRA:BTP
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Active Biotech AB (FRA:BTP) Overvalued in 2026?

Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued. The current stock price of €0.47 is trading 262.7% above its estimated GF Value™ of €0.13. GuruFocus considers Active Biotech AB to be Significantly Overvalued.

Key valuation signals for FRA:BTP:

  • Net Loan:
  • GF Value™: €0.13 vs. price of €0.47 (262.7% above fair value)
  • GF Score™: 34/100 with 1 warning sign

No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Active Biotech AB Business Description

Other Exchanges ACTI:Sweden0GQU:UK
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
34GF Score

Get the complete analysis for FRA:BTP

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.47
Price
€0.13
GF Value